China Biologic Products (CBPO) Lifted to Buy at BidaskClub

Share on StockTwits

BidaskClub upgraded shares of China Biologic Products (NASDAQ:CBPO) from a hold rating to a buy rating in a research report report published on Wednesday morning.

A number of other research analysts have also weighed in on CBPO. Zacks Investment Research lowered shares of China Biologic Products from a hold rating to a strong sell rating in a research note on Thursday, August 9th. ValuEngine lowered shares of China Biologic Products from a hold rating to a sell rating in a research note on Friday, August 24th. Finally, Morgan Stanley lowered shares of China Biologic Products from an overweight rating to an equal weight rating and set a $84.00 target price on the stock. in a research note on Monday, November 5th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and two have given a buy rating to the company. China Biologic Products currently has a consensus rating of Hold and an average target price of $95.33.

CBPO opened at $76.77 on Wednesday. China Biologic Products has a 1-year low of $60.08 and a 1-year high of $107.44. The company has a market capitalization of $2.70 billion, a price-to-earnings ratio of 19.24, a price-to-earnings-growth ratio of 5.95 and a beta of 1.45.

China Biologic Products (NASDAQ:CBPO) last released its earnings results on Thursday, November 1st. The biopharmaceutical company reported $0.96 earnings per share for the quarter, missing the Zacks’ consensus estimate of $1.09 by ($0.13). China Biologic Products had a return on equity of 11.44% and a net margin of 15.50%. The business had revenue of $119.10 million during the quarter, compared to analysts’ expectations of $122.00 million. During the same period last year, the business earned $1.32 earnings per share. The company’s revenue for the quarter was up 19.6% compared to the same quarter last year. As a group, sell-side analysts predict that China Biologic Products will post 3.43 earnings per share for the current fiscal year.

Several hedge funds have recently added to or reduced their stakes in CBPO. Gabelli Funds LLC purchased a new stake in shares of China Biologic Products during the 3rd quarter valued at approximately $232,000. Fox Run Management L.L.C. purchased a new stake in shares of China Biologic Products during the 3rd quarter valued at approximately $262,000. Myriad Asset Management Ltd. purchased a new stake in shares of China Biologic Products during the 2nd quarter valued at approximately $348,000. GABELLI & Co INVESTMENT ADVISERS INC. purchased a new stake in shares of China Biologic Products during the 3rd quarter valued at approximately $352,000. Finally, Jane Street Group LLC purchased a new stake in shares of China Biologic Products during the 2nd quarter valued at approximately $461,000. 48.63% of the stock is currently owned by hedge funds and other institutional investors.

About China Biologic Products

China Biologic Products Holdings, Inc engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia.

Featured Article: How to invest in a bear market

Receive News & Ratings for China Biologic Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.